|
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- FDA Approves Alectinib for ALK-Positive Lung Cancer
Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
- ALK+ NSCLC Treatment Guidelines
Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
- A comprehensive evaluation of ALK inhibitors in the first . . .
There are currently six ALK inhibitors available for the first-line treatment of patients diagnosed with ALK-positive advanced non-small cell lung cancer (NSCLC) However, clinicians face challenges in selecting the most appropriate drug for treatment We have collated pertinent evaluative evidence and undertaken a multifaceted assessment of the enrolled medications across five critical
- Anaplastic lymphoma kinase (ALK)-positive advanced non-small . . .
The molecular pathogenesis, clinical features, and treatment of NSCLC associated with the ALK fusion oncogene are discussed here An overview of the treatment of metastatic NSCLC, ALK-positive early NSCLC, and the methods and indications for molecular testing are presented elsewhere
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK . . .
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy recommended for patients with ALK -positive non–small cell lung cancer (NSCLC) 1 Lorlatinib is a brain-penetrant, third-generation ALK TKI that has greater coverage of ALK resistance mutations than second-generation ALK inhibitors 2, 3 In
- Treatment of metastatic ALK-positive non-small cell lung . . .
This comprehensive study, spanning over a decade, provides crucial insights into the clinical characteristics, treatment patterns, and resistance mechanisms of advanced ALK-positive NSCLC, where median OS exceeds 5 years Re-biopsies during treatment are essential for advancing our understanding of …
- Advanced ALK-Positive NSCLC: Treatment Sequencing Insights . . .
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured multiple studies on treatment strategies for patients with advanced anaplastic lymphoma kinase (ALK)-positive non
|
|
|